摘要
目的：讨拉米夫定与阿德福韦酯治疗乙肝肝纤维化的对比分析。方法选取2013年11月～2014年12月我院接诊的45例乙肝肝纤维化患者，按照入院的先后顺序分为两组，22例对照组给予阿德福韦酯，23例研究组给予拉米夫定，观察两组患者的治疗效果。结果研究组患者的治疗总有效率、child-Pugh评分、HBV DNA水平及肝纤维化指标优于对照组，P＜0.05，差异具有统计学意义。结论拉米夫定治疗乙肝肝纤维化的效果显著，可以有效提高治疗的总有效率，降低肝纤维化水平。
Objective Lamivudine and adefovir dipivoxil medication in treatment of hepatitis B hepatic fibrosis are to be comparatively studied. Methods Choose 45 patients of hepatitis B hepatic ifbrosis who are received and treated in hospital from November 2013 to December 2014 and separate them into two groups according to their hospitalization sequence, 22 patients in control group are given adefovir dipivoxil medication treatment, while 23 patients in study group are given lamivudine medication treatment, and then observe and compare treatment effects between two groups. ResultsPatients’ treatment efifcacy and Childe-Pugh score, their HBV and DNA level and index of hepatitis B hepatic ifbrosis in study group are much more favorable than counterparts in control group; there is a treatment differential between two groups, and such a differential has statistic value （P〈0.05）.Conclusion Lamivudine medication is of efifcacy in treatment of hepatitis B hepatic ifbrosis; it is conducive to improving patients’ treatment efifcacy and decreasing level of hepatitis B hepatic ifbrosis.
出处
《中国继续医学教育》
2015年第10期223-224,共2页
China Continuing Medical Education
关键词
拉米夫定
阿德福韦酯
乙肝
肝纤维化
Lamivudine
Adefovir Dipivoxil
Hepatitis B
Hepatic Fibrosis
